
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated a solid financial performance, marked by an increase in revenue estimates and the raising of FY24 revenue guidance to a range of $320 million to $330 million due to strong results across its product offerings. The company reported a significant year-over-year increase of 81% in test volume for the IDgenetix test, highlighting its unique position in the marketplace and the favorable traction for its diagnostic solutions designed for a variety of cancers. Additionally, consistent commercial execution, recent acquisitions, and positive reimbursement decisions for newer products underline the growth potential in the dermatologic and gastroenterology markets, contributing to an optimistic outlook for the company.
Bears say
Castle Biosciences Inc faces several fundamental challenges that contribute to a negative outlook for its stock. The company heavily relies on government and commercial reimbursement rates for its diagnostic tests, which are susceptible to fluctuations, potentially impacting revenue stability. Furthermore, there are concerns regarding competition for new products, the risk of underperformance in tests currently under development, and the firm's historical pattern of operating at losses, raising the likelihood for additional capital requirements that may not be attainable.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares